summit clinical trial tirzepatide In the trial, researchers examined cardiovascular outcomes of treatment with in patients with heart failure with preserved ejection fraction and obesity. Full results and Plain Language Summary: https://nej.md/4hRGaTY Medthreads Tirzepatide for maintenance of bodyweight

However, invasive options like bariatric surgery or liposuction isnt for everyone, especially if there may be underlying health conditions at play

Lancet Diabetes & Endocrinology commission on the definition and diagnosis of clinical obesity

doi: 10.1016/s8756-3282(02)00688-9

While these findings have not been linked to serious adverse outcomes so far, they highlight the need for long-term safety studies, which are currently underway in Phase 3 trials

To date, all CVOTs for dipeptidyl peptidase 4 (DPP-4) inhibitors, 4-7 glucagon-like peptide-1 receptor agonists (GLP-1 RAs), 8-13 and sodium-glucose transport protein 2 (SGLT-2) inhibitors 14-16 have documented a lack of increased CV risk (non-inferiority) with the investigational product in patients with T2DM compared to placebo

What is the difference between orforglipron and semaglutide